<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="publisher-id">DIJ</journal-id><journal-id journal-id-type="hwp">spdij</journal-id><journal-title>Therapeutic Innovation &amp; Regulatory Science</journal-title><issn pub-type="ppub">2168-4790</issn><issn pub-type="epub">2164-9200</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1177/2168479013487541</article-id><article-id pub-id-type="publisher-id">10.1177_2168479013487541</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Trials</subject></subj-group></article-categories><title-group><article-title>A Framework for Managing the Minimal Clinically Important Difference in Clinical Trials</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Koynova</surname><given-names>Denitsa</given-names></name><degrees>PhD, MSc PME</degrees><xref ref-type="aff" rid="aff1-2168479013487541">1</xref><xref ref-type="corresp" rid="corresp1-2168479013487541"/></contrib><contrib contrib-type="author"><name><surname>Lühmann</surname><given-names>Reinhold</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff2-2168479013487541">2</xref></contrib><contrib contrib-type="author"><name><surname>Fischer</surname><given-names>Renate</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3-2168479013487541">3</xref></contrib></contrib-group><aff id="aff1-2168479013487541"><label>1</label>Pharmaceutical professional, Düsseldorf, Germany</aff><aff id="aff2-2168479013487541"><label>2</label>Statistical consultant, Allensbach, Germany</aff><aff id="aff3-2168479013487541"><label>3</label>Clinical development professional, Heidelberg, Germany</aff><author-notes><corresp id="corresp1-2168479013487541">Denitsa Koynova Email: <email>denitsa.koynova@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>7</month><year>2013</year></pub-date><volume>47</volume><issue>4</issue><fpage>447</fpage><lpage>454</lpage><history><date date-type="received"><day>1</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>2</day><month>4</month><year>2013</year></date></history><permissions><copyright-statement>© The Author(s) 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder content-type="other">Drug Information Association</copyright-holder></permissions><abstract><p>There is a long history of discussions about what is a <italic>minimal clinically important difference</italic> (MCID) and how this term applies to clinical research. This paper deals with a practical framework for MCID and its applicability to clinical trials. A literature review on the topic confirmed the fundamental role of MCID for the clinical research, although no guide on how to best use the MCID in clinical trials was identified. We propose a framework that takes into account (1) the definition of MCID as a term when random variable is discussed, (2) a 4-level approach for classifying the MCID evidence to be considered in a clinical development program, and (3) a method of MCID evaluation, defined in a scientifically sound protocol. The proposed framework can prompt and steer stakeholders to improve the methodological sense of clinical trials based on the definition of MCID at the level of efficacy or safety, increase the quality of data derived from clinical trials and reporting of results, and allow effective planning of drug development programs.</p></abstract><kwd-group><kwd>clinical research</kwd><kwd>clinical trials</kwd><kwd>clinical relevance</kwd><kwd>MCID</kwd><kwd>framework</kwd></kwd-group></article-meta></front><body><sec id="section1-2168479013487541"><title>Introduction</title><p>In the clinical trial environment, the disease status is measured by means of the change in the primary variable from a baseline to an end point. This choice should allow a clear, quantitatively measureable benefit of a given intervention (treatment). According to the International Conference on Harmonisation, Topic E9, “the primary variable (target, variable, primary endpoint) should be the variable capable of providing the most clinically relevant and convincing evidence directly related to the primary objective of the trial.”<sup><xref ref-type="bibr" rid="bibr1-2168479013487541">1</xref></sup> Thus, the process of identifying new and potential treatments is not just about showing a statistical significance but also about quantitating the clinical relevance.<sup><xref ref-type="bibr" rid="bibr2-2168479013487541">2</xref></sup></p><p>While statistical significance indicates that the likelihood of a difference observed following a treatment is not caused by chance alone, clinical relevance identifies the magnitude of a difference and whether such relevance is large enough to show clinical benefit.<sup><xref ref-type="bibr" rid="bibr2-2168479013487541">2</xref></sup> The CONSORT (Consolidated Standards of Reporting Trials) statement and its accompanying explanation and elaboration paper have also drawn attention to the importance of defining and reporting clinical importance in clinical trials: “the difference between statistical significance and clinical importance should always be borne in mind.”<sup><xref ref-type="bibr" rid="bibr3-2168479013487541">3</xref></sup></p><p>The perception about the clinical importance has changed with the introduction of the concept of the minimal clinically important difference (MCID). The MCID was defined as the smallest change in an outcome, perceived as beneficial by patients.<sup><xref ref-type="bibr" rid="bibr4-2168479013487541">4</xref></sup> An important recognition derived from the MCID is that statistically significant differences do not necessarily translate into clinically important or relevant benefits.<sup><xref ref-type="bibr" rid="bibr5-2168479013487541">5</xref></sup> Study results are considered statistically significant when values indicating the lower limit of the 95% confidence interval (95% CI) are greater than the null effect.<sup><xref ref-type="bibr" rid="bibr6-2168479013487541">6</xref></sup> The judgment of clinical importance depends on the relationship between the MCID of the intervention to the point estimate of the efficacy of the intervention and the 95% CI surrounding it.<sup><xref ref-type="bibr" rid="bibr6-2168479013487541">6</xref></sup> Consequently, the clinical importance can take 4 forms: <italic>definite</italic> (MCID is smaller than the lower limit of the 95% CI), <italic>probable</italic> (MCID is greater than the lower limit of the 95% CI but smaller than the point estimate of the efficacy of the intervention), <italic>possible</italic> (MCID is less than the upper limit of the 95% CI but greater than the point of estimate of the efficacy of intervention), and <italic>definitely not</italic> (MCID is greater than the upper limit of the 95% CI).<sup><xref ref-type="bibr" rid="bibr6-2168479013487541">6</xref></sup> Man-Son-Hing et al<sup><xref ref-type="bibr" rid="bibr6-2168479013487541">6</xref></sup> have further used the actual clinical trials to show the different combinations in the relationship between statistical significance and clinical importance. Thus, in some reports, MCID was considered a bridge between evidence-based and patient-oriented medicine, connecting the magnitude of desired effect sizes in randomized clinical trials to the amount of benefits that patients considered relevant.<sup><xref ref-type="bibr" rid="bibr7-2168479013487541">7</xref></sup> In other reports, the value of MCID was used as a determinant for the sample size in a clinical trial and thus influenced the study design.<sup><xref ref-type="bibr" rid="bibr8-2168479013487541">8</xref>,<xref ref-type="bibr" rid="bibr9-2168479013487541">9</xref></sup></p><p>Over the past 30 years, there have been several attempts to define the optimum MCID measure,<sup><xref ref-type="bibr" rid="bibr10-2168479013487541">10</xref></sup> but without a consensus on the appropriate methods for determining and using it.<sup><xref ref-type="bibr" rid="bibr11-2168479013487541">11</xref></sup> An overview of reported definitions is summarized in <xref ref-type="table" rid="table1-2168479013487541">Table 1</xref>.<sup><xref ref-type="bibr" rid="bibr12-2168479013487541">12</xref><xref ref-type="bibr" rid="bibr13-2168479013487541"/><xref ref-type="bibr" rid="bibr14-2168479013487541"/><xref ref-type="bibr" rid="bibr15-2168479013487541"/><xref ref-type="bibr" rid="bibr16-2168479013487541"/><xref ref-type="bibr" rid="bibr17-2168479013487541"/><xref ref-type="bibr" rid="bibr18-2168479013487541"/><xref ref-type="bibr" rid="bibr19-2168479013487541"/><xref ref-type="bibr" rid="bibr20-2168479013487541"/><xref ref-type="bibr" rid="bibr21-2168479013487541"/><xref ref-type="bibr" rid="bibr22-2168479013487541"/><xref ref-type="bibr" rid="bibr23-2168479013487541"/><xref ref-type="bibr" rid="bibr24-2168479013487541"/><xref ref-type="bibr" rid="bibr25-2168479013487541"/><xref ref-type="bibr" rid="bibr26-2168479013487541"/><xref ref-type="bibr" rid="bibr27-2168479013487541"/><xref ref-type="bibr" rid="bibr28-2168479013487541"/><xref ref-type="bibr" rid="bibr29-2168479013487541"/>–<xref ref-type="bibr" rid="bibr30-2168479013487541">30</xref></sup> Some of the current challenges to achieve consensus include the use of different approaches to define the MCID (eg, clinician consensus panels, distribution-based approaches, and anchor-based approaches), which produce different MCID values,<sup><xref ref-type="bibr" rid="bibr19-2168479013487541">19</xref>,<xref ref-type="bibr" rid="bibr31-2168479013487541">31</xref></sup> different MCID definitions that do not take into consideration the cost of treatment,<sup><xref ref-type="bibr" rid="bibr5-2168479013487541">5</xref>,<xref ref-type="bibr" rid="bibr19-2168479013487541">19</xref></sup> and methodological and psychometric issues that have been overlooked in earlier investigations<sup><xref ref-type="bibr" rid="bibr11-2168479013487541">11</xref></sup> affecting the possibility to consolidate the concept of MCID. The Federal Drug Administration (FDA) also attempted to provide guidance on the use of MCID in the drafted guideline on patient-reported outcomes.<sup><xref ref-type="bibr" rid="bibr24-2168479013487541">24</xref></sup> However, any mention of the term <italic>MCID</italic> has been removed in later publications.<sup><xref ref-type="bibr" rid="bibr32-2168479013487541">32</xref></sup> At the same time, the literature continues reporting underestimation of the clinical importance in trials where outcomes are mainly based on the statistical significance of the results.<sup><xref ref-type="bibr" rid="bibr6-2168479013487541">6</xref>,<xref ref-type="bibr" rid="bibr33-2168479013487541">33</xref>,<xref ref-type="bibr" rid="bibr34-2168479013487541">34</xref></sup> This lack of consensus for the use of MCID in clinical trials and the importance and relevance of this topic prompted us to describe in the current paper the practical framework for the use and implications of MCID in clinical trials.</p><table-wrap id="table1-2168479013487541" position="float"><label>Table 1.</label><caption><p>Examples of published definitions for clinical significance.</p></caption><graphic alternate-form-of="table1-2168479013487541" xlink:href="10.1177_2168479013487541-table1.tif"/><table><thead><tr><th>Definitions<sup>a</sup></th><th>Topic</th><th>Approach to Define Minimal Clinically Important Difference </th></tr></thead><tbody><tr><td>Clinical significance </td><td/><td/></tr><tr><td> Level of functioning subsequent to therapy that places clients closer to the mean of the functional population than it does to the mean of the dysfunctional population.<sup><xref ref-type="bibr" rid="bibr12-2168479013487541">12</xref></sup></td><td>Psychotherapy</td><td>Reliable change index</td></tr><tr><td> Magnitude of change that is statistically reliable and by the end of therapy ensures clients to end up in a range that renders them indistinguishable from well-functioning people.<sup><xref ref-type="bibr" rid="bibr13-2168479013487541">13</xref></sup></td><td>Psychotherapy</td><td>Reliable change index</td></tr><tr><td> End-state functioning that falls within a normative range on important measures.<sup><xref ref-type="bibr" rid="bibr14-2168479013487541">14</xref></sup></td><td>Psychology</td><td>Normative comparison</td></tr><tr><td> Relates to 1 of 2 issues: (1) whether a difference between a quality-of-life score and a comparison value is clinically meaningful or (2) whether a change in quality of life over time is not only statistically but also clinically meaningful.<sup><xref ref-type="bibr" rid="bibr15-2168479013487541">15</xref></sup></td><td>Quality of life</td><td>Anchor-based approach</td></tr><tr><td>Minimal/minimum clinically important difference</td><td/><td/></tr><tr><td> Smallest difference in scores in the domain of interest that patients perceive as beneficial and would mandate, in the absence of troublesome side effects and excessive cost, a change in the patient’s management.<sup><xref ref-type="bibr" rid="bibr4-2168479013487541">4</xref></sup></td><td>Quality of life</td><td>Mean change in scores</td></tr><tr><td> Minimum amount of change that is considered clinically meaningful.<sup><xref ref-type="bibr" rid="bibr16-2168479013487541">16</xref></sup></td><td>Rheumatoid arthritis</td><td>Expert panel approach</td></tr><tr><td> Smallest change or difference in an outcome measure that is perceived as beneficial and that would lead to a change in the patient’s medical management, assuming an absence of excessive side effects and costs.<sup><xref ref-type="bibr" rid="bibr17-2168479013487541">17</xref></sup></td><td>Rheumatoid arthritis</td><td>Anchor-based approach</td></tr><tr><td> Lower boundary of change that has been defined, in some way, to be important.<sup><xref ref-type="bibr" rid="bibr18-2168479013487541">18</xref></sup></td><td>Overall</td><td>Statistical-, anchor-, and opinion-based approaches</td></tr><tr><td> Represents a change that would be considered meaningful and worthwhile by the patient such that he or she would consider repeating the intervention if it were his or her choice. The MCID is a threshold value for such a change.<sup><xref ref-type="bibr" rid="bibr19-2168479013487541">19</xref></sup></td><td>Spinal surgery</td><td>Anchor-based and distribution-based approaches</td></tr><tr><td> Smallest change that is important to patients.<sup><xref ref-type="bibr" rid="bibr20-2168479013487541">20</xref></sup></td><td>Low back pain</td><td>Anchor-based approach</td></tr><tr><td>Minimal clinically important improvement</td><td/><td/></tr><tr><td> Smallest change in measurement that signifies an important improvement in a patient’s symptom and in clinical trials and provides readers with additional information on the effect size by expressing the results more meaningfully.<sup><xref ref-type="bibr" rid="bibr21-2168479013487541">21</xref></sup></td><td>Knee and hip osteoarthritis</td><td>Anchor-based approach</td></tr><tr><td> Minimum change potentially detectable</td><td/><td/></tr><tr><td> Conditional standard error of measurement.<sup><xref ref-type="bibr" rid="bibr22-2168479013487541">22</xref></sup></td><td>Low back pain</td><td>Statistical approach</td></tr><tr><td>Minimally important difference</td><td/><td/></tr><tr><td> Smallest score difference on a health-related quality-of-life questionnaire that is clinically significant and therefore likely to be meaningful to both patients and clinicians.<sup><xref ref-type="bibr" rid="bibr23-2168479013487541">23</xref></sup></td><td>Breast cancer</td><td>Distribution-based and anchor-based approach</td></tr><tr><td> The amount of difference or change observed in a patient-reported outcome (PRO) measure between treatment groups in a clinical trial that will be interpreted as a treatment benefit.<sup><xref ref-type="bibr" rid="bibr24-2168479013487541">24</xref></sup></td><td>PRO</td><td>Regulatory perspective</td></tr><tr><td>Minimal metrically detectable change</td><td/><td/></tr><tr><td> What difference a real signal represents among the noise associated with the measurement error. The signal is defined as MMDC.<sup><xref ref-type="bibr" rid="bibr25-2168479013487541">25</xref></sup></td><td>Disability measured by the Functional Autonomy Measuring System</td><td>Psychometric method</td></tr><tr><td>Minimal perceptible difference/change</td><td/><td/></tr><tr><td> Difference or change on the measurement scale associated with the smallest change in health status detectable by the patient.<sup><xref ref-type="bibr" rid="bibr26-2168479013487541">26</xref></sup></td><td>Osteoarthritis</td><td>Anchor-based approach</td></tr><tr><td>Minimal patient perceivable improvement/deterioration</td><td/><td/></tr><tr><td> Smallest average change in a domain score that patients perceive as a clinically important improvement/deterioration.<sup><xref ref-type="bibr" rid="bibr27-2168479013487541">27</xref></sup></td><td>Asthma</td><td>Anchor-based approach</td></tr><tr><td>Sufficiently important difference</td><td/><td/></tr><tr><td> Smallest amount of patient-valued benefit that an intervention would require justifying associated costs, risks, and other harms.<sup><xref ref-type="bibr" rid="bibr7-2168479013487541">7</xref></sup></td><td>Overall</td><td>Benefit-harm trade-off method</td></tr><tr><td>Smallest detectable difference</td><td/><td/></tr><tr><td> Smallest effect that can be detected as significant by the chosen statistical method.<sup><xref ref-type="bibr" rid="bibr28-2168479013487541">28</xref></sup></td><td>Osteoarthritis</td><td>Transition method</td></tr><tr><td> Difference beyond random error of the measurement.<sup><xref ref-type="bibr" rid="bibr29-2168479013487541">29</xref></sup></td><td>Imaging </td><td>Distribution-based approach, opinion-based model, and data-driven model</td></tr><tr><td> Smallest change in score that can be reliably discriminated from the measurement error of the scoring method.<sup><xref ref-type="bibr" rid="bibr30-2168479013487541">30</xref></sup></td><td>Rheumatoid arthritis</td><td>Anchor-based approach</td></tr><tr><td> The smallest amount of change that can reliably be distinguished from random measurement error.<sup><xref ref-type="bibr" rid="bibr16-2168479013487541">16</xref></sup></td><td>Rheumatoid arthritis</td><td>Expert panel approach</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1a-2168479013487541"><p><sup>a</sup>The definitions are citations from the original source.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section2-2168479013487541" sec-type="materials|methods"><title>Materials and Methods</title><p>Overall, 122 sources that included and/or discussed the topic of clinical significance and MCID were reviewed. The majority of the sources were retrieved from PubMed. The search was restricted to publications in the English language. The keywords used included <italic>clinical significance</italic>, <italic>minimal clinically important difference</italic>, <italic>minimal important difference</italic>, <italic>minimal detectable change</italic>, and <italic>clinical significance and methods for evaluation</italic>. Several identified articles contained useful references and related sources of information that were also reviewed and used. To cover a broad range of MCID reports, we included publications that varied according to the type (review, research, opinion/commentary), year of publication (before 1992 to 2012), clinical indications, and the scope of discussion on MCID (<xref ref-type="table" rid="table2-2168479013487541">Table 2</xref>).</p><table-wrap id="table2-2168479013487541" position="float"><label>Table 2.</label><caption><p>Summary of reviewed literature sources.</p></caption><graphic alternate-form-of="table2-2168479013487541" xlink:href="10.1177_2168479013487541-table2.tif"/><table><thead><tr><th>Characteristics</th><th>No. of Source Publications Reviewed</th></tr></thead><tbody><tr><td>Sources reviewed</td><td>122</td></tr><tr><td>Type of paper</td><td/></tr><tr><td> Research papers</td><td>71</td></tr><tr><td> Opinion/commentary </td><td>31</td></tr><tr><td> Review papers</td><td>20</td></tr><tr><td>Year of publication</td><td/></tr><tr><td> 2006-2012</td><td>40</td></tr><tr><td> 1999-2005</td><td>61</td></tr><tr><td> 1992-1998</td><td>15</td></tr><tr><td> Before 1992</td><td>6</td></tr><tr><td>Medical specialty</td><td/></tr><tr><td> <italic>Indication specified</italic></td><td>90</td></tr><tr><td> Pain</td><td>23</td></tr><tr><td> Pulmonology</td><td>19</td></tr><tr><td> Rheumatology</td><td>12</td></tr><tr><td> Orthopedics</td><td>9</td></tr><tr><td> Central nervous system</td><td>5</td></tr><tr><td> Others (eg, oncology, cardiology, dentistry)</td><td>22</td></tr><tr><td> <italic>No indication specified</italic></td><td>32</td></tr><tr><td>Scope of discussion</td><td/></tr><tr><td> Methods for measuring clinical significance/MCID</td><td>56</td></tr><tr><td> MCID of specific questionnaires</td><td>42</td></tr><tr><td> Use of clinical significance/MCID in clinical trials</td><td>14</td></tr><tr><td> Guidelines (regulatory authorities, groups)</td><td>10</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1-2168479013487541"><p>MCID, minimal clinically important difference.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section3-2168479013487541"><title>Results and Discussion</title><p>We found many sources in the literature dealing with MCID measurement and its application in several clinical indications. However, during our search, it became apparent that there was no available framework for the management of MCID that could support the pharmaceutical professionals during the planning of clinical trials. To overcome this, we propose an MCID framework by taking into account the following:<list list-type="order"><list-item><p>MCID definition to be provided as a term when random variable is used,</p></list-item><list-item><p>four-level classification of the MCID evidence to be considered in a clinical development program, <italic>and</italic></p></list-item><list-item><p>method of MCID evaluation to be defined in a scientifically sound protocol.</p></list-item></list></p><sec id="section4-2168479013487541"><title>MCID Definition</title><p>As shown in <xref ref-type="table" rid="table1-2168479013487541">Table 1</xref>, several definitions for MCID have been used in the literature. The assortment of terminology corresponds to the diversity of methods used to determine the value of MCID<sup><xref ref-type="bibr" rid="bibr19-2168479013487541">19</xref>,<xref ref-type="bibr" rid="bibr31-2168479013487541">31</xref></sup> and depends also on the perspective — clinicians, patients, clinical research scientists, or payers. Therefore, when MCID of a random variable is discussed within the scope of a clinical trial, a clear definition of the MCID is essential.</p><p>Clinicians often use impressions regarding the significance of outcomes of a clinical trial. Such impressions are based on their experience or practices that define which change of a score is clinically relevant, and these in turn are used for future treatment regimens. MCID is usually determined by a group of clinical experts who have used specific measuring instruments in clinical practice and in clinical trials. An example of a consensus review group is the Initiative on Methods, Measures and Pain Assessment in Clinical Trials, which recommended a 30% change in a self-report back pain measurement as a general barometer for a clinically relevant change.<sup><xref ref-type="bibr" rid="bibr35-2168479013487541">35</xref></sup> Another example is the OMERACT Imaging Task Force that recommended MCID for plain films in rheumatoid arthritis to be defined by expert panels.<sup><xref ref-type="bibr" rid="bibr16-2168479013487541">16</xref></sup></p><p>Patients can also gauge the impact of a treatment and assess the significance of the outcome, and many MCID thresholds are being used for this purpose. An example is the difference in scores of patients who, compared with other patients, rate themselves as “a little better” or “a little worse” instead of “about the same.”<sup><xref ref-type="bibr" rid="bibr36-2168479013487541">36</xref></sup> In this context, it should be noted that studies of human memory indicate that retrospective evaluations of past experience are fallible with possible recall bias when patients’ intrapersonal judgments are applied.<sup><xref ref-type="bibr" rid="bibr37-2168479013487541">37</xref></sup> Furthermore, it is of interest to read the results of the experiment reported by Wells et al,<sup><xref ref-type="bibr" rid="bibr38-2168479013487541">38</xref></sup> who arranged one-to-one conversations between patients to determine MCID and observed that patients generally tended to judge themselves as less disabled than others. Indeed, patients may vary in the value they place on a particular benefit such that a patient may place a different value on the same benefit depending on the other patient.<sup><xref ref-type="bibr" rid="bibr8-2168479013487541">8</xref></sup> Overall, it appears that patients’ own assessment is highly individualized and often inconsistent across different interventions.<sup><xref ref-type="bibr" rid="bibr39-2168479013487541">39</xref></sup></p><p>Clinical research scientists, dealing with clinical trials, provide a value to clinical relevance through distribution (statistical) methods and anchor (external measure) methods, both of which have been described by Crosby et al.<sup><xref ref-type="bibr" rid="bibr40-2168479013487541">40</xref></sup> The distribution method is based on the spread of the scores of the measure of interest around the mean, while the anchor method compares scores of the measure of interest with other outcome measures. The majority of MCID definitions are deduced from these 2 groups of methods.</p><p>Finally, the health policy makers assess clinical relevance of treatment against the occurrence of adverse events, level of inconvenience, and societal costs.<sup><xref ref-type="bibr" rid="bibr8-2168479013487541">8</xref></sup></p><p>When defining the MCID, it should be recognized that a single value for MCID may not be applicable for all studied populations and that MCID may be specific for the disease and population under investigation. The intraindividual and interindividual variability also plays an important role such that, due to the natural variability, there might be some patients exceeding the threshold of clinical relevance. In addition, any method used to estimate the value of MCID may be limited by the manner in which the participants are recruited.<sup><xref ref-type="bibr" rid="bibr41-2168479013487541">41</xref></sup> Specific inclusion and exclusion criteria are usually applied in each clinical trial, and this may lead to samples of patients with different distributions of MCID, making the trials and ensuing results not easily comparable. Furthermore, the smallest change derived from the distribution-based methods deals with statistical significance<sup><xref ref-type="bibr" rid="bibr42-2168479013487541">42</xref></sup> rather than with a clinically relevant change. Therefore, the term, such as <italic>minimal detectable change</italic>, is not adequate when the aim of a clinical trial is to detect clinical relevance of a treatment. It would appear that the most useful final MCID definition might be the one that is derived from the application of more than one approach tested in multiple settings.<sup><xref ref-type="bibr" rid="bibr8-2168479013487541">8</xref>,<xref ref-type="bibr" rid="bibr43-2168479013487541">43</xref></sup> The FDA patient-reported outcome guideline from 2006 supports this view through the very reasonable statement: “if an MID (minimum important difference) is to be applied to clinical study results, it is generally helpful to use a variety of methods to discover whether concordance among methods confirms the choice of an MID.”<sup><xref ref-type="bibr" rid="bibr24-2168479013487541">24</xref></sup></p></sec><sec id="section5-2168479013487541"><title>Four-Level Approach to Classify the MCID Evidence</title><p>The 4-level approach for classifying the MCID evidence is summarized in <xref ref-type="fig" rid="fig1-2168479013487541">Figure 1</xref>.</p><fig id="fig1-2168479013487541" position="float"><label>Figure 1.</label><caption><p>Four-level approach for classifying the minimal clinically important difference (MCID) evidence.</p></caption><graphic xlink:href="10.1177_2168479013487541-fig1.tif"/></fig><p>For MCID evidence level 1, 4 specific methodological requirements, described below, should be met. Only if <italic>all</italic> 4 requirements are fulfilled is it meaningful to estimate the MCID. In such a case, the measurement error of the instrument used is the lower limit of the MCID, and the following considerations would apply:<list list-type="bullet"><list-item><p>The MCID can only be estimated if the random variable under consideration is valid. Thus, the random variable measures a change, which is directly related to the disease under investigation. It is usually expected that this relation is well known.</p></list-item><list-item><p>The relation (increasing or decreasing) between the disease and the variable should be monotone.</p></list-item><list-item><p>There should be a reliable measurement instrument available. This implies that it should be possible to measure the variable with a sufficiently high precision.</p></list-item><list-item><p>The variable/measurement should be sufficiently responsive, such that a change in the disease should also lead to a consistent change in the measured values.</p></list-item></list></p><p>Level 2 MCID evidence refers to trials for which the clinical importance is defined based on sources that advocate evidence-based medicine/randomized clinical trials (RCTs) such as the Cochrane library, whereas level 3 considers values of clinical importance deduced from general databases, such as ClinicalTrials.gov.</p><p>Level 4 MCID evidence considers the situation when the methodological evidence is still insufficient. At this level, the risk management comes into force. Level 4 MCID evidence might be a potential source for risks that need to be discussed and mitigated. The risk management is a common approach used during the project development, and it is defined in a risk management plan. A risk management plan deals with the processes of conducting risk management actions based on identification, analysis, response planning, monitoring, and control of potential or real risks of a treatment.<sup><xref ref-type="bibr" rid="bibr44-2168479013487541">44</xref></sup> The objective of a risk management plan in a project (be it a clinical trial or a whole clinical development program) is to increase the probability and impact of positive events and decrease the probability and impact of negative events. Such an approach is already established for the pharmacovigilance of clinical trials, with the purpose to set “activities and interventions designed to identify, characterize, prevent or minimize risks relating to medicinal products, and the assessment of the effectiveness of those interventions.”<sup><xref ref-type="bibr" rid="bibr45-2168479013487541">45</xref></sup></p><p>Ideally, level 1 MCID evidence should be used during all stages of a drug development program. However, considering the challenges, an alternative option could be considered as follows: level 4 MCID evidence should be used as a starting point for a phase IIa trial (evaluating clinical pharmacology parameters such as dose/concentration effect, in a small number of patients—up to 200—with target disease). As the clinical development program progresses (ie, phase IIb, expanding the efficacy and safety knowledge on a larger scale study in several hundred patients with target disease, to formally assess the dose-response relationship), the precision of the MCID measurement should increase, introducing evidence from level 3 and level 2 MCID. Level 1 evidence should be targeted for the phase III pivotal trials.</p><p>The concept of the 4-level approach used to classify the MCID evidence originates from the principle of the evidence-based medicine that applies the best available evidence gained through scientific methods to clinical decision making.<sup><xref ref-type="bibr" rid="bibr46-2168479013487541">46</xref></sup> This concept assesses the strength of evidence for the risks and benefits of treatments (including lack of treatment) and diagnostic tests.<sup><xref ref-type="bibr" rid="bibr47-2168479013487541">47</xref></sup> Systems have been developed that help to gauge this evidence according to the type and quality of clinical trials—for example, level 1 evidence (obtained from RCTs) and level 4 evidence (opinions collected from respected opinion leaders or authorities, clinical experience, or descriptive studies).<sup><xref ref-type="bibr" rid="bibr48-2168479013487541">48</xref></sup> The presented MCID 4-level approach is a new classification that extends the current evidence-based principles applied in the clinical trial context and provides a methodologically sound approach for the use of MCID in clinical development programs.</p></sec><sec id="section6-2168479013487541"><title>MCID Evaluation Protocol</title><p>The last part of the proposed framework deals with the method for MCID evaluation. These should be described in a protocol that defines the methodology used, including possible generalizations and assumptions, such as the MCID estimated in adult population and its applicability to a pediatric population. The protocol follows the well-known practice from the operational side of the clinical trials that states “what is not written has not been done.”</p><p>With sufficient interest in the topic from the sponsors of clinical studies (pharmaceutical companies, university institutes), competent authorities, and payers, the framework proposed by us can serve as the basis to develop a guide for the best Good MCID Practice (G-MCID-P).</p></sec></sec><sec id="section7-2168479013487541"><title>Conclusion</title><p>The proposed MCID framework is a useful tool for using and managing the MCID in clinical trials and clinical development programs. The approach steers the involved parties to (1) improve the methodological sense of clinical trials with regard to the definition of MCID at the level of efficacy or safety, (2) increase the quality of data derived from clinical trials and reporting of results, and (3) allow better planning of drug development programs. We anticipate that the application of the proposed framework for MCID in clinical trials will positively affect the communication between pharmaceutical companies that are often the sponsors of clinical trials, competent authorities, and payers.</p></sec></body><back><ack><title>Acknowledgment</title><p>This paper is based on the thesis of D. Koynova from the Master of Science in Pharmaceutical Medicine at the University of Duisburg-Essen, Faculty of Medicine, Essen, Germany. We thank Waldemar Braun for providing the list with MCID terms and his expert opinion on the topic.</p></ack><fn-group><fn fn-type="conflict" id="fn1-2168479013487541"><label>Declaration of Conflicting Interests</label><p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure" id="fn2-2168479013487541"><label>Funding</label><p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-2168479013487541"><label>1</label><citation citation-type="journal"><collab collab-type="author">International Conference on Harmonisation</collab>. <source>E9: Statistical Principles for Clinical Trials</source>. <year>1998</year>. <ext-link ext-link-type="uri" xlink:href="http://www.ich.org">http://www.ich.org</ext-link>.</citation></ref><ref id="bibr2-2168479013487541"><label>2</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>R</given-names></name></person-group>. <source>Statistical Thinking for Non-Statisticians in Drug Regulation</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>John Wiley</publisher-name>; <year>2009</year>.</citation></ref><ref id="bibr3-2168479013487541"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Hopewell</surname><given-names>S</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><etal/></person-group>. <article-title>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomized trials</article-title>. <source>BMJ</source>. <year>2010</year>;<volume>340</volume>:<fpage>c869</fpage>.</citation></ref><ref id="bibr4-2168479013487541"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaeschke</surname><given-names>R</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name></person-group>. <article-title>Measurement of health status: ascertaining the minimal clinically important difference</article-title>. <source>Control Clin Trials</source>. <year>1989</year>;<volume>10</volume>:<fpage>407</fpage>–<lpage>415</lpage>.</citation></ref><ref id="bibr5-2168479013487541"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gatchel</surname><given-names>RJ</given-names></name><name><surname>Mayer</surname><given-names>TG</given-names></name><name><surname>Chou</surname><given-names>R</given-names></name></person-group>. <article-title>What does/should the minimum clinically important difference measure? A reconsideration of its clinical value in evaluating efficacy of lumbar fusion surgery</article-title>. <source>Clin J Pain</source>. <year>2012</year>;<volume>28</volume>:<fpage>387</fpage>–<lpage>397</lpage>.</citation></ref><ref id="bibr6-2168479013487541"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Man-Son-Hing</surname><given-names>M</given-names></name><name><surname>Laupacis</surname><given-names>A</given-names></name><name><surname>Rourke</surname><given-names>O’</given-names></name><etal/></person-group>. <article-title>Determination of the clinical importance of study results</article-title>. <source>J Gen Intern Med</source>. <year>2002</year>;<volume>17</volume>:<fpage>469</fpage>–<lpage>476</lpage>.</citation></ref><ref id="bibr7-2168479013487541"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>B</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Mundt</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name></person-group>. <article-title>Sufficiently important difference: expanding the framework of clinical significance</article-title>. <source>Med Decis Making</source>. <year>2005</year>;<volume>25</volume>:<fpage>250</fpage>–<lpage>261</lpage>.</citation></ref><ref id="bibr8-2168479013487541"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Osoba</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>AW</given-names></name><etal/></person-group>. <article-title>Methods to explain the clinical significance of health status measures</article-title>. <source>Mayo Clin Proc</source>. <year>2002</year>;<volume>77</volume>:<fpage>371</fpage>–<lpage>383</lpage>.</citation></ref><ref id="bibr9-2168479013487541"><label>9</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ringash</surname><given-names>J</given-names></name><name><surname>O’Sullivan</surname><given-names>B</given-names></name><name><surname>Bezjak</surname><given-names>A</given-names></name><name><surname>Redelmeier</surname><given-names>D</given-names></name></person-group>. <article-title>Interpreting clinically significant changes in patient-reported outcomes. 2007</article-title>. <ext-link ext-link-type="uri" xlink:href="www.interscience.wiley.com">www.interscience.wiley.com</ext-link>. <comment>Accessed January 21, 2011.</comment></citation></ref><ref id="bibr10-2168479013487541"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spratt</surname><given-names>KF</given-names></name></person-group>. <article-title>Patient-level minimal clinically important difference based on clinical judgment and minimally detectable measurement difference: a rationale for the SF-36 physical function scale in the SPORT intervertebral disc herniation cohort</article-title>. <source>Spine</source>. <year>2009</year>;<volume>34</volume>:<fpage>1722</fpage>–<lpage>1731</lpage>.</citation></ref><ref id="bibr11-2168479013487541"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gatchel</surname><given-names>RJ</given-names></name><name><surname>Lurie</surname><given-names>JD</given-names></name><name><surname>Mayer</surname><given-names>TG</given-names></name></person-group>. <article-title>Minimal clinically important difference</article-title>. <source>Spine</source>. <year>2010</year>;<volume>35</volume>:<fpage>1739</fpage>–<lpage>1743</lpage>.</citation></ref><ref id="bibr12-2168479013487541"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>NS</given-names></name><name><surname>Truax</surname><given-names>P</given-names></name></person-group>. <article-title>Clinical significance: a statistical approach to defining meaningful change in psychotherapy research</article-title>. <source>J Consult Clin Psychol</source>. <year>1991</year>;<volume>59</volume>:<fpage>12</fpage>–<lpage>19</lpage>.</citation></ref><ref id="bibr13-2168479013487541"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>NS</given-names></name><name><surname>Roberts</surname><given-names>LJ</given-names></name><name><surname>Berns</surname><given-names>SB</given-names></name><name><surname>McGlinchey</surname><given-names>JB</given-names></name></person-group>. <article-title>Methods for defining and determining the clinical significance of treatment effects: description, application, and alternatives</article-title>. <source>J Consult Clin Psychol</source>. <year>1999</year>;<volume>67</volume>:<fpage>300</fpage>–<lpage>307</lpage>.</citation></ref><ref id="bibr14-2168479013487541"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kendall</surname><given-names>PC</given-names></name><name><surname>Marrs-Garcia</surname><given-names>A</given-names></name><name><surname>Nath</surname><given-names>SR</given-names></name><name><surname>Sheldrick</surname><given-names>RC</given-names></name></person-group>. <article-title>Normative comparisons for the evaluation of clinical significance</article-title>. <source>J Consult Clin Psychol</source>. <year>1999</year>;<volume>67</volume>:<fpage>285</fpage>–<lpage>299</lpage>.</citation></ref><ref id="bibr15-2168479013487541"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>C</given-names></name><name><surname>Barofsky</surname><given-names>I</given-names></name></person-group><collab collab-type="author">;</collab> <collab collab-type="author">Clinical Significance Consensus Meeting Group</collab>. <article-title>Groups vs individual approaches to understanding the clinical significance of differences or changes in quality of life</article-title>. <source>Mayo Clin Proc</source>. <year>2002</year>;<volume>77</volume>:<fpage>384</fpage>–<lpage>392</lpage>.</citation></ref><ref id="bibr16-2168479013487541"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Lassere</surname><given-names>M</given-names></name><name><surname>Edmonds</surname><given-names>J</given-names></name><name><surname>Kirwan</surname><given-names>J</given-names></name><name><surname>Strand</surname><given-names>V</given-names></name><name><surname>Boers</surname><given-names>M</given-names></name></person-group><article-title>, for the OMERACT Imaging Task Force. Minimal clinically important difference in plain films in RA: group discussions, conclusions, and recommendations. OMERACT Imaging Task Force</article-title>. <source>J Rheumatol</source>. <year>2001</year>;<volume>28</volume>:<fpage>914</fpage>–<lpage>917</lpage>.</citation></ref><ref id="bibr17-2168479013487541"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Maxwell</surname><given-names>L</given-names></name><name><surname>MacLean</surname><given-names>R</given-names></name><name><surname>Tugwell</surname><given-names>P</given-names></name></person-group>. <article-title>Determining the minimal clinically important difference in activity, fatigue, and sleep quality in patients with rheumatoid arthritis</article-title>. <source>J Rheumatol</source>. <year>2007</year>;<volume>34</volume>:<fpage>280</fpage>–<lpage>289</lpage>.</citation></ref><ref id="bibr18-2168479013487541"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beaton</surname><given-names>DE</given-names></name><name><surname>Boers</surname><given-names>M</given-names></name><name><surname>Wells</surname><given-names>G</given-names></name></person-group>. <article-title>Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research</article-title>. <source>Curr Opin Rheumatol</source>. <year>2002</year>;<volume>14</volume>:<fpage>109</fpage>–<lpage>114</lpage>.</citation></ref><ref id="bibr19-2168479013487541"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Copay</surname><given-names>AG</given-names></name><name><surname>Subach</surname><given-names>BR</given-names></name><name><surname>Glassman</surname><given-names>SD</given-names></name><name><surname>Polly</surname><given-names>DW</given-names><suffix>Jr</suffix></name><name><surname>Schuler</surname><given-names>TC</given-names></name></person-group>. <article-title>Understanding the minimum clinically important difference: a review of concepts and methods</article-title>. <source>Spine J</source>. <year>2007</year>;<volume>7</volume>:<fpage>541</fpage>–<lpage>546</lpage>.</citation></ref><ref id="bibr20-2168479013487541"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stratford</surname><given-names>PW</given-names></name><name><surname>Binkley</surname><given-names>JM</given-names></name><name><surname>Riddle</surname><given-names>DL</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name></person-group>. <article-title>Sensitivity to change of the Roland-Moriss Back Pain Questionnaire: part 1</article-title>. <source>Phys Ther</source>. <year>1998</year>;<volume>78</volume>:<fpage>1186</fpage>–<lpage>1196</lpage>.</citation></ref><ref id="bibr21-2168479013487541"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tubach</surname><given-names>F</given-names></name><name><surname>Ravaud</surname><given-names>P</given-names></name><name><surname>Baron</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement</article-title>. <source>Ann Rheum Dis</source>. <year>2005</year>;<volume>64</volume>:<fpage>29</fpage>–<lpage>33</lpage>.</citation></ref><ref id="bibr22-2168479013487541"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stratford</surname><given-names>PW</given-names></name><name><surname>Binkley</surname><given-names>J</given-names></name><name><surname>Soloman</surname><given-names>P</given-names></name><name><surname>Finch</surname><given-names>E</given-names></name><name><surname>Gill</surname><given-names>C</given-names></name><name><surname>Moreland</surname><given-names>J</given-names></name></person-group>. <article-title>Defining the minimum level of detectable change for the Roland-Morris questionnaire</article-title>. <source>Phys Ther</source>. <year>1996</year>;<volume>76</volume>:<fpage>359</fpage>–<lpage>368</lpage>.</citation></ref><ref id="bibr23-2168479013487541"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eton</surname><given-names>DT</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Yost</surname><given-names>KJ</given-names></name><etal/></person-group>. <article-title>A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale</article-title>. <source>J Clin Epidemiol</source>. <year>2004</year>;<volume>57</volume>:<fpage>898</fpage>–<lpage>910</lpage>.</citation></ref><ref id="bibr24-2168479013487541"><label>24</label><citation citation-type="journal"><collab collab-type="author">Food and Drug Administration. Guidance for industry</collab>. <article-title>Patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance</article-title>. <source>Health Qual Life Outcomes</source>. <year>2006</year>;<volume>4</volume>:<fpage>79</fpage>.</citation></ref><ref id="bibr25-2168479013487541"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hébert</surname><given-names>R</given-names></name><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name></person-group>. <article-title>Setting the minimal metrically detectable change on disability rating scales</article-title>. <source>Arch Phys Med Rehabil</source>. <year>1997</year>;<volume>78</volume>:<fpage>1305</fpage>–<lpage>1308</lpage>.</citation></ref><ref id="bibr26-2168479013487541"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ehrich</surname><given-names>EW</given-names></name><name><surname>Davies</surname><given-names>GM</given-names></name><name><surname>Watson</surname><given-names>DJ</given-names></name><name><surname>Bolognese</surname><given-names>JA</given-names></name><name><surname>Seidenberg</surname><given-names>BC</given-names></name><name><surname>Bellamy</surname><given-names>N</given-names></name></person-group>. <article-title>Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis</article-title>. <source>J Rheumatol</source>. <year>2000</year>;<volume>27</volume>:<fpage>2635</fpage>–<lpage>2641</lpage>.</citation></ref><ref id="bibr27-2168479013487541"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>BL</given-names></name><name><surname>Santanello</surname><given-names>NC</given-names></name><name><surname>Epstein</surname><given-names>RS</given-names></name></person-group>. <article-title>Impact of the global on patient perceivable change in an asthma specific QOL questionnaire</article-title>. <source>Qual Life Res</source>. <year>1996</year>;<volume>5</volume>:<fpage>117</fpage>–<lpage>122</lpage>.</citation></ref><ref id="bibr28-2168479013487541"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Angst</surname><given-names>F</given-names></name><name><surname>Aeschlimann</surname><given-names>A</given-names></name><name><surname>Stucki</surname><given-names>G</given-names></name></person-group>. <article-title>Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities</article-title>. <source>Arthritis Care Res</source>. <year>2001</year>;<volume>45</volume>:<fpage>384</fpage>–<lpage>391</lpage>.</citation></ref><ref id="bibr29-2168479013487541"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lassere</surname><given-names>MN</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>KR</given-names></name></person-group>. <article-title>Foundations of the minimal clinically important difference for imaging</article-title>. <source>J Rheumatol</source>. <year>2001</year>;<volume>28</volume>:<fpage>890</fpage>–<lpage>891</lpage>.</citation></ref><ref id="bibr30-2168479013487541"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bruynesteyn</surname><given-names>K</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Boers</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference</article-title>. <source>Arthritis Rheum</source>. <year>2002</year>;<volume>46</volume>:<fpage>913</fpage>–<lpage>920</lpage>.</citation></ref><ref id="bibr31-2168479013487541"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Montori</surname><given-names>V</given-names></name><name><surname>Devereaux</surname><given-names>PJ</given-names></name><name><surname>Schünemann</surname><given-names>H</given-names></name><name><surname>Bhandari</surname><given-names>M</given-names></name></person-group>. <article-title>Patients at the center: in our practice, and in our use of language</article-title>. <source>ACP J Club</source>. <year>2004</year>;<volume>140</volume>:<fpage>A11</fpage>–<lpage>A12</lpage>.</citation></ref><ref id="bibr32-2168479013487541"><label>32</label><citation citation-type="book"><collab collab-type="author">Food and Drug Administration (FDA)</collab>. <source>Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims</source>. <publisher-loc>Silver Spring, MD</publisher-loc>: <publisher-name>FDA</publisher-name>; <comment>December 2009.</comment></citation></ref><ref id="bibr33-2168479013487541"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Tulder</surname><given-names>M</given-names></name><name><surname>Malmivaara</surname><given-names>A</given-names></name><name><surname>Hayden</surname><given-names>J</given-names></name><name><surname>Koes</surname><given-names>B</given-names></name></person-group>. <article-title>Statistical significance versus clinical importance: trials on exercise therapy for chronic low back pain</article-title>. <source>Spine</source>. <year>2007</year>;<volume>32</volume>(<issue>16</issue>):<fpage>1785</fpage>–<lpage>1790</lpage>.</citation></ref><ref id="bibr34-2168479013487541"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Molnar</surname><given-names>FJ</given-names></name><name><surname>Man-Son-Hing</surname><given-names>M</given-names></name><name><surname>Fergusson</surname><given-names>D</given-names></name></person-group>. <article-title>Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia</article-title>. <source>J Am Geriatr Soc</source>. <year>2009</year>;<volume>57</volume>(<issue>3</issue>):<fpage>536</fpage>–<lpage>546</lpage>.</citation></ref><ref id="bibr35-2168479013487541"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dworkin</surname><given-names>RH</given-names></name><name><surname>Turk</surname><given-names>DC</given-names></name><name><surname>Farrar</surname><given-names>JT</given-names></name></person-group>. <article-title>Core outcome measure for chronic pain clinical trails: IMMPACT recommendation</article-title>. <source>Pain</source>. <year>2005</year>;<volume>113</volume>:<fpage>9</fpage>–<lpage>19</lpage>.</citation></ref><ref id="bibr36-2168479013487541"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burnard</surname><given-names>B</given-names></name><name><surname>Kernant</surname><given-names>WN</given-names></name><name><surname>Feinstein</surname><given-names>AR</given-names></name></person-group>. <article-title>Indexes and boundaries for “quantitative significance” in statistical decisions</article-title>. <source>J Clin Epidemiol</source>. <year>1990</year>;<volume>43</volume>:<fpage>1273</fpage>–<lpage>1284</lpage>.</citation></ref><ref id="bibr37-2168479013487541"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Redelmeier</surname><given-names>D</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Goldstein</surname><given-names>R</given-names></name></person-group>. <article-title>On the debate over methods for estimating the clinically important difference</article-title>. <source>J Clin Epidemiol</source>. <year>1996</year>;<volume>49</volume>:<fpage>1223</fpage>–<lpage>1224</lpage>.</citation></ref><ref id="bibr38-2168479013487541"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Tugwell</surname><given-names>P</given-names></name><name><surname>Kraag</surname><given-names>GR</given-names></name><name><surname>Baker</surname><given-names>PR</given-names></name><name><surname>Groh</surname><given-names>J</given-names></name><name><surname>Redelmeier</surname><given-names>DA</given-names></name></person-group>. <article-title>Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective</article-title>. <source>J Rheumatol</source>. <year>1993</year>;<volume>20</volume>:<fpage>557</fpage>–<lpage>560</lpage>.</citation></ref><ref id="bibr39-2168479013487541"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bellamy</surname><given-names>N</given-names></name><name><surname>Carr</surname><given-names>A</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>Shea</surname><given-names>B</given-names></name><name><surname>Wells</surname><given-names>G</given-names></name></person-group>. <article-title>Towards a definition of “difference” in osteoarthritis</article-title>. <source>J Rheumatol</source>. <year>2001</year>;<volume>28</volume>:<fpage>427</fpage>–<lpage>430</lpage>.</citation></ref><ref id="bibr40-2168479013487541"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crosby</surname><given-names>RD</given-names></name><name><surname>Kolotkin</surname><given-names>RL</given-names></name><name><surname>Williams</surname><given-names>GR</given-names></name></person-group>. <article-title>Defining clinically meaningful change in health-related quality of life</article-title>. <source>J Clin Epidemiol</source>. <year>2003</year>;<volume>56</volume>:<fpage>395</fpage>–<lpage>407</lpage>.</citation></ref><ref id="bibr41-2168479013487541"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Redelmeier</surname><given-names>DA</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Goldstein</surname><given-names>RS</given-names></name></person-group>. <article-title>Assessing the minimal important difference in symptoms: a comparison of two techniques</article-title>. <source>J Clin Epidemiol</source>. <year>1996</year>;<volume>49</volume>:<fpage>1215</fpage>–<lpage>1219</lpage>.</citation></ref><ref id="bibr42-2168479013487541"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Vet</surname><given-names>HC</given-names></name><name><surname>Terwee</surname><given-names>CB</given-names></name><name><surname>Ostelo</surname><given-names>RW</given-names></name><name><surname>Beckerman</surname><given-names>H</given-names></name><name><surname>Knol</surname><given-names>DL</given-names></name><name><surname>Bouter</surname><given-names>LM</given-names></name></person-group>. <article-title>Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change</article-title>. <source>Health Qual Life Outcomes</source>. <year>2006</year>;<volume>4</volume>:<fpage>54</fpage>.</citation></ref><ref id="bibr43-2168479013487541"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sloan</surname><given-names>JA</given-names></name></person-group>. <article-title>Assessing the minimally clinically significant difference: scientific considerations, challenges, and solutions</article-title>. <source>COPD</source>. <year>2005</year>;<volume>2</volume>:<fpage>57</fpage>–<lpage>62</lpage>.</citation></ref><ref id="bibr44-2168479013487541"><label>44</label><citation citation-type="book"><collab collab-type="author">Project Management Institute</collab>. <source>A Guide to the Project Management Body of Knowledge</source>. <fpage>4th</fpage> ed. <ext-link ext-link-type="uri" xlink:href="http://www.pmi.org">http://www.pmi.org</ext-link>. <comment>Accessed December 2, 2010.</comment></citation></ref><ref id="bibr45-2168479013487541"><label>45</label><citation citation-type="web"><collab collab-type="author">European Medicines Agency, Committee for Medicinal Products for Human Use</collab>. <article-title>Guideline on risk management systems for medicinal products for human use. 2005 updated in Volume 9a</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu">http://www.ema.europa.eu</ext-link>. <comment>Accessed January 5, 2011.</comment></citation></ref><ref id="bibr46-2168479013487541"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Timmermans</surname><given-names>S</given-names></name><name><surname>Mauck</surname><given-names>A</given-names></name></person-group>. <article-title>The promises and pitfalls of evidence-based medicine</article-title>. <source>Health Aff</source>. <year>2005</year>;<volume>24</volume>:<fpage>18</fpage>–<lpage>28</lpage>.</citation></ref><ref id="bibr47-2168479013487541"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elstein</surname><given-names>AS</given-names></name></person-group>. <article-title>On the origins and development of evidence-based medicine and medical decision making</article-title>. <source>Inflamm Res</source>. <year>2004</year>;<volume>53</volume>:<fpage>184</fpage>–<lpage>189</lpage>.</citation></ref><ref id="bibr48-2168479013487541"><label>48</label><citation citation-type="book"><collab collab-type="author">US Preventive Services Task Force</collab>. <source>Procedure Manual</source>. <comment>Section 4, 4.3.2.</comment> <ext-link ext-link-type="uri" xlink:href="http://www.uspreventiveservicestaskforce.org">http://www.uspreventiveservicestaskforce.org</ext-link>. <comment>Accessed January 5, 2011.</comment></citation></ref></ref-list></back></article>